Health Care Reform

Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period.

Four distinct issues covered in the survey results highlight specific aspects of American health care that are falling short.

As more states pass laws regarding gender-affirming care, employers need to take a close look at how they structure their health care benefit plans.

Specialty drug trend continued to be driven primarily by claim utilization, accounting for nearly three-quarters of the overall 14.1% gross trend.

Once the pandemic subsided, there was a spike in gene therapy approvals, with four therapies released in 2022, which sent a clear message that the Food and Drug Administration is reshifting its focus to progressive therapies, such as a new therapeutic treatment of glaucoma.

Hospital system pricing is closely related to mergers and acquisitions, as consolidations drive up already inordinate health care costs, according to the attorney general of North Carolina, where health care is a leading cause of personal debt.